EpiBiome is a precision microbiome engineering company developing sustainable, FDA-approvable microbiome-based therapies to combat infectious disease in humans and agriculture without antibiotics. The company is led by CEO/co-founder Nick Conley, PhD, with co-founders and senior leaders Aeron Tynes Hammack, PhD; Christina Tsai, PhD; Lucia Mokres, DVM; and Bruno Marchon, PhD. EpiBiome plans to use recent financing to ramp up laboratory automation, advance its drug development programs, and purchase additional lab equipment for a new facility. Financially, it secured a $1M debt facility from Silicon Valley Bank and earlier closed a $6M Series A in January. The Series A included investment from Viking Global Investors via Illumina Accelerator Boost Capital, Matrix Capital Management, Alexandria Venture Investments, SV Tech Ventures, China Rock Capital Management and China Ding Cheng Holding Group. The company graduated from the inaugural class of the Illumina Accelerator. EpiBiome is a South San Francisco, CA–based precision microbiome engineering company focused on developing FDA‑approved therapies that combat infectious disease in humans and in agriculture without using small‑molecule antibiotics. Its first product is aimed at treating bovine mastitis, an udder inflammation in dairy cows that causes approximately $35 billion in global losses and $2 billion in U.S. losses due to reduced milk production and quality. The company intends to develop alternatives to small‑molecule antibiotics for agricultural use and to invest in its microbiome engineering platform. EpiBiome also plans to file for additional patents on its technology. Leadership listed in the article includes CEO Dr. Nick Conley, COO Aaron Tynes Hammack, PhD, CSO Christina Tsai, PhD, CMO Lucia Mokres, DVM, and CTO Bruno Marchon, PhD. The company recently completed a $6M Series A financing to advance these plans.

Total raised

$7M

Funding rounds

2

Latest round

Debt Financing

Latest activity

Jun 2016